Evidence map›Paper›PMID 41803138›Full record

ArticleNature communications2026

Dual phagocytosis-checkpoint blockade revitalizes immune surveillance in mouse models of glioblastoma.

JongHoon Ha, Yifan Wang, Yifan Ma, Annette Wu, Shiyan Dong, Seong Dong Jeong, Jared L Edwards, Mengyu Chang, Yen-Tzu Chang, Xiaotian Wang and 24 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

34 authors.

JongHoon HaDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Yifan WangDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-7387-0654
Yifan MaDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-9371-4365
Annette WuDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0009-0005-8343-4748
Shiyan DongDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0003-2912-8895
Seong Dong JeongDepartment of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0009-0003-5163-3924
Jared L EdwardsDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0009-0008-7604-3441
Mengyu ChangDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Yen-Tzu ChangDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Xiaotian WangDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Maurice DufilhoDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Michelle Najarro TorresDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Shannon McCabeDepartment of Neurosurgery, University of Arizona, Tucson, AZ, USA.ORCID http://orcid.org/0000-0002-9230-7477
Weiye DengDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0003-4243-5013
Adam J GrippinDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-8076-4240
Jeffrey S WeinbergDepartment of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-5587-6673
Shaan M RazaDepartment of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Franco DeMonteDepartment of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ian E McCutcheonDepartment of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-1638-3400
Sujit PrabhuDepartment of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sherise D FergusonDepartment of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Chibawanye I EneDepartment of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-2653-281X
Kadir AkdemirDepartment of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0003-2299-2373
Sreyashi BasuJames P. Allison Institute, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-5028-3833
Sonali JindalJames P. Allison Institute, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-3911-6815
Benjamin R SchrankDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-8138-4250
Jian HuDepartment of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-9760-2013
Sangeeta GoswamiDepartment of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-9201-4503
Vinay K PuduvalliThe Brain Tumor Center, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-8396-9500
Frederick F LangDepartment of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0003-3747-873X
Kristin HuntoonDepartment of Neurosurgery, University of Arizona, Tucson, AZ, USA.ORCID http://orcid.org/0000-0002-7211-8986
Padmanee SharmaJames P. Allison Institute, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0003-4658-055X
Betty Y S KimDepartment of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. bykim@mdanderson.org.ORCID http://orcid.org/0000-0001-6890-8355
Wen JiangDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. wjiang4@mdanderson.org.ORCID http://orcid.org/0000-0001-9154-633X

Funding

Therapeutic targeting of multiple glioblastoma phagocytosis checkpoints using a novel bispecific antibodyR01NS117828 · NINDS · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI JIANG, WEN · 2021 to 2025
$2.2M
Harnessing ecDNA Detection in Antigen-Presenting Cells for Anti-Tumor ImmunityK08CA296776 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Benjamin R Schrank · 2025 to 2026
$278k
NCI NIH HHS K08 CA296776NINDS NIH HHS R01 NS117828
6 · The paper itself

Abstract

Macrophage-mediated phagocytosis of tumor cells elicits potent antitumor immunity. Nonetheless, sole-blockade of the anti-phagocytosis molecule CD47 has yielded insufficient therapeutic outcomes. Here, we report that glioblastoma (GBM) cells expressed abundant levels of phagocytosis checkpoint CD24. We further show that dual blockade of CD24 and CD47 synergistically enhances the pro-phagocytic activity of macrophages, thereby improving tumor antigen cross-presentation and activating the cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) pathway. This innate immune activation facilitates T cell infiltration into tumors and sensitizes tumors to anti-PD1 therapy, improving survival outcomes in murine GBM models, including immunosuppressive tumors reflecting human GBM-like features. Thus, our results indicate that dual-phagocytosis checkpoint blockade offers a promising therapeutic avenue to potentiate cancer immunotherapy.

Indexed as

Brain NeoplasmsGlioblastomaImmune Checkpoint InhibitorsImmunologic SurveillancePhagocytosisAnimalsCD24 AntigenCD47 AntigenCell Line, TumorcGAS-STING Signaling PathwayCross-PrimingCyclic Guanosine Monophosphate-Adenosine Monophosphate SynthaseDisease Models, AnimalFemaleHumansImmunotherapyCD24 AntigenCD47 AntigencGAS protein, mouseCyclic Guanosine Monophosphate-Adenosine Monophosphate SynthaseImmune Checkpoint InhibitorsMembrane ProteinsProgrammed Cell Death 1 ReceptorSting1 protein, mouseSTING Protein

Identifiers

PMID41803138
PMCPMC13103327

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.